
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc. is positioned positively due to the advancements in its pipeline candidates, particularly with the focus on high-value indications, which signifies a potential for considerable market impact. The company's POZ Platform delivery technology enhances drug precision, which could lead to significant competitive advantages over existing treatment options, addressing notable limitations in current biocompatible polymers. Furthermore, the anticipated clinical success of pipeline candidates like SER-270, alongside the growing approval footprint of SER-252, suggests potential long-term upside that is currently unaccounted for in the company's valuation assessments.
Bears say
Serina Therapeutics reported a net loss of $0.64 per share, which significantly exceeds previous estimates, reflecting worsening financial conditions. The company faces multiple fundamental risks, including challenges in advancing its lead candidate, SER-252, through necessary clinical evaluations and regulatory approvals, which are critical for its future revenue potential. Additionally, the projected full-year 2025 net loss has escalated to $2.01, indicating ongoing financial strain and potential dilution risks that may further impact investor sentiment.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares